Form 8-K - Current report:
SEC Accession No. 0001104659-24-027005
Filing Date
2024-02-23
Accepted
2024-02-23 16:01:30
Documents
14
Period of Report
2024-02-22
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm247136d1_8k.htm   iXBRL 8-K 32518
  Complete submission text file 0001104659-24-027005.txt   206439

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA nbse-20240222.xsd EX-101.SCH 3048
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE nbse-20240222_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nbse-20240222_pre.xml EX-101.PRE 22381
15 EXTRACTED XBRL INSTANCE DOCUMENT tm247136d1_8k_htm.xml XML 3512
Mailing Address 350 TECHNOLOGY DRIVE PITTSBURGH PA 15219
Business Address 350 TECHNOLOGY DRIVE PITTSBURGH PA 15219 412-763-3350
NeuBase Therapeutics, Inc. (Filer) CIK: 0001173281 (see all company filings)

EIN.: 465622433 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35963 | Film No.: 24671024
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)